Cybrexa Therapeutics Completes Successful Pre-IND Meeting With FDA for CBX-12 (alphalex™-exatecan), a Novel Treatment for Solid Tumors NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...

Cybrexa Therapeutics Announces CBX-12 as Lead Development Program NEW HAVEN, Conn., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...